Repeat radiation therapy combined with the monoclonal antibody drug bevacizumab extended progression-free survival in patients with recurrent glioblastoma, according to findings from a recent clinical trial published in the ...
Apr 10, 2023
0
21
A unique drug derived from oleic acid—which naturally occurs in animal and vegetable fats such as olive oil—has shown promise for patients with an advanced form of the most common type of brain cancer, following a study ...
Feb 22, 2024
0
48
Neoadjuvant immune checkpoint blockade (ICB) is a promising treatment for melanoma and other cancer types, and has recently been shown to provide a modest survival benefit for patients with recurrent glioblastoma. To improve ...
Jun 29, 2021
0
13
A new brain cancer vaccine tailored to individual patients by using material from their own tumors has proven effective in a multicenter phase 2 clinical trial at extending their lives by several months or longer. The patients ...
Apr 17, 2012
0
0
Targeting two brain tumor-associated proteins—rather than one—with CAR T cell therapy shows promise as a strategy for reducing solid tumor growth in patients with recurrent glioblastoma (GBM), an aggressive form of brain ...
Mar 13, 2024
0
90
Many glioblastoma patients treated with bevacizumab (Avastin) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according ...
Jun 1, 2013
0
0
An experimental gene therapy essentially doubled the overall survival of patients with recurrent glioblastoma compared to the current standard of care, a researcher said Oct. 1 at the Cancer Therapy & Research Center (CTRC) ...
Oct 1, 2015
0
60
Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with anti-angiogenic drugs and which will not. In patients newly diagnosed with the dangerous brain tumor glioblastoma, ...
Nov 4, 2013
0
0
For patients with recurrent glioblastoma, treatment with chimeric antigen receptor (CAR) T-cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, in addition to the wild-type ...
Mar 23, 2024
0
2
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.
Jan 23, 2018
0
7
